At ASCO 2024 last month, editor in chief Jonah Comstock caught up with Dr Andree Amelsberg, SVP of global and US medical affairs at Eisai to chat about what the company was sharing at the conference.
In the video below, Amelsberg describes some new data from the CLEAR study looking at lenvatinib plus pembrolizumab in renal cell cancer and how that data on biomarkers and progression will help inform treating physicians.
He also discusses some of Eisai’s other research at the conference including on ADCs, and talks about the benefits of partnering with other companies to bring drugs to market. Finally, Comstock and Amelsberg talk about one of the biggest overall trends at the show: The rising importance of personalised treatment and the biomarkers and diagnostics necessary to make that personalisation a reality.
Check out the video for the whole conversation from the show floor in Chicago.
Subscribe to the pharmaphorum KZfaq channel for in-depth conversations with innovators across healthcare: / @pharmaphorum
Join us on Twitter for the latest news, features, event coverage, and discussions: / pharmaphorum
And for everything, everywhere, all at once, visit our official site: pharmaphorum.com/